NOVOZYMES A/S financials
NOVOZYMES A/S
529900T6WNZXD2R3JW38 | Line item | 2026 | 2025-12-31 | 2025-06-30 |
|---|---|---|---|
| Income statement | |||
| Revenue | €2.24B | — | €2.10B |
| Cost of sales | €979.1M | — | €957.3M |
| Gross profit | €1.26B | — | €1.14B |
| Administrative expenses | €121.7M | — | €113.9M |
| Operating profit (EBIT) | €519.6M | — | €458.0M |
| Net finance income / (cost) | -€38.5M | — | -€35.0M |
| Profit before tax | €478.5M | — | €419.2M |
| Income tax expense | €107.7M | — | €96.4M |
| Profit for the year | €370.8M | — | €322.8M |
| — attributable to owners | €370.8M | — | €322.8M |
| Total comprehensive income | €548.2M | — | -€116.0M |
| Per share | |||
| Basic EPS | €0.80 | — | €0.69 |
| Diluted EPS | €0.80 | — | €0.69 |
| Free cash flow / share | €0.75 | — | €0.66 |
| Cash flow statement | |||
| Net cash from operating activities | €523.3M | — | €426.5M |
| Income taxes paid | €47.0M | — | €8.7M |
| Net cash from investing activities | -€267.2M | — | -€1.58B |
| Purchase of PP&E (capex) | €177.6M | — | €118.0M |
| Purchase of intangibles | €38.6M | — | €19.4M |
| Net cash from financing activities | -€232.1M | — | €1.21B |
| Dividends paid | €265.1M | — | €262.4M |
| Proceeds from borrowings | €41.3M | — | €1.70B |
| Repayments of borrowings | €1.70B | — | €164.8M |
| Net change in cash | €24.0M | — | €54.1M |
| Balance sheet | |||
| Total assets | €16.63B | €16.35B | €16.40B |
| Non-current assets | €14.55B | €14.37B | €14.35B |
| Property, plant & equipment | €3.15B | €3.00B | €2.83B |
| Intangible assets & goodwill | €6.31B | €6.19B | €6.15B |
| Current assets | €2.08B | €1.98B | €2.05B |
| Inventories | €836.3M | €772.2M | €799.6M |
| Trade & other receivables | €792.1M | €716.5M | €704.4M |
| Cash & equivalents | €308.7M | €275.3M | €328.2M |
| Total equity | €11.15B | €10.86B | €10.74B |
| Non-current liabilities | €4.28B | €2.75B | €4.49B |
| Long-term borrowings | €2.83B | €1.30B | €2.97B |
| Current liabilities | €1.20B | €2.74B | €1.17B |
| Deferred tax liabilities | €1.29B | €1.32B | €1.37B |
| Derived metrics | |||
| Free cash flow | €345.7M | — | €308.5M |
| Operating margin | 23.2% | — | 21.9% |
| Net margin | 16.6% | — | 15.4% |
| Return on equity | 3.3% | — | 3.0% |
| Cash conversion ratio | 1.41× | — | 1.32× |
| Capex coverage | 2.95× | — | 3.61× |
| Other reported items | |||
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €51.5M | — | €1.46B |
| Changes In Equity | €299.7M | — | -€433.1M |
| Comprehensive Income Attributable To Owners of Parent | €548.2M | — | -€116.0M |
| Current Borrowings and Current Portion of Noncurrent Borrowings | €237.3M | €1.70B | €347.0M |
| Current Contract Assets | €19.6M | €35.9M | €12.7M |
| Current Contract Liabilities | €23.2M | €26.0M | €27.8M |
| Current Tax Assets Current | €6.7M | €46.0M | €27.0M |
| Current Tax Liabilities Current | €150.7M | €116.7M | €126.9M |
| Decrease Increase Through Tax On Sharebased Payment Transactions | -€2.0M | — | €4.2M |
| Deferred Tax Assets | €245.1M | €242.2M | €265.7M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | €9.4M | — | -€5.9M |
| Equity and Liabilities | €16.63B | €16.35B | €16.40B |
| Gains Losses On Cash Flow Hedges Before Tax | -€18.2M | — | €53.9M |
| Gains Losses On Exchange Differences On Translation Before Tax | €201.3M | — | -€481.2M |
| Increase Decrease In Cash and Cash Equivalents | €33.4M | — | €48.2M |
| Increase Decrease In Working Capital | €240.8M | — | €240.5M |
| Increase Decrease Through Sharebased Payment Transactions | €9.0M | — | €11.7M |
| Intangible Assets Other Than Goodwill | €4.81B | €4.90B | €5.05B |
| Interest Paid Classified As Operating Activities | €36.6M | — | €23.1M |
| Interest Received Classified As Operating Activities | €9.9M | — | €11.1M |
| Investments In Associates Accounted For Using Equity Method | €14.9M | €17.5M | €20.2M |
| Issued Capital | €125.4M | €125.5M | €125.6M |
| Liabilities | €5.48B | €5.49B | €5.66B |
| Noncurrent Contract Liabilities | €79.0M | €79.9M | €87.0M |
| Noncurrent Provisions | €40.3M | €23.5M | €29.1M |
| Other Adjustments For Noncash Items | €467.0M | — | €364.9M |
| Other Comprehensive Income | €177.4M | — | -€438.8M |
| Other Current Financial Assets | €4.9M | €20.3M | €37.2M |
| Other Current Liabilities | €419.8M | €476.3M | €367.3M |
| Other Current Receivables | €112.9M | €117.0M | €142.8M |
| Other Noncurrent Financial Assets | €15.7M | €13.6M | €15.9M |
| Other Noncurrent Liabilities | €36.7M | €29.2M | €29.3M |
| Other Noncurrent Receivables | €7.6M | €5.9M | €6.1M |
| Other Operating Income Expense | €8.8M | — | €6.1M |
| Payments To Acquire Or Redeem Entitys Shares | €0 | — | €99.9M |
| Proceeds From Issue of Bonds Notes and Debentures | €1.69B | — | €0 |
| Proceeds From Sale Or Issue of Treasury Shares | €5.6M | — | €37.7M |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | €500.0K | — | €18.0M |
| Purchase of Treasury Shares | — | — | €99.9M |
| Research and Development Expense | €240.8M | — | €216.9M |
| Sale Or Issue of Treasury Shares | €5.6M | — | €37.7M |
| Share of Profit Loss of Associates Accounted For Using Equity Method | -€2.6M | — | -€3.8M |
| Trade and Other Current Payables To Trade Suppliers | €366.3M | €420.8M | €302.1M |
| Undrawn Borrowing Facilities | €940.5M | — | — |
Every line item above is a fact tagged in NOVOZYMES A/S's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.